Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.


PURPOSE To determine what the influence is of dyspnea (CTCAE3.0) before high-dose radiotherapy (RT) on the incidence and severity of subsequent lung toxicity in patients with non-small cell lung cancer (NSCLC). METHODS In 197 patients with stage I-III NSCLC maximal dyspnea scores (CTCAE3.0) were obtained prospectively at three time periods: before RT, the… (More)
DOI: 10.1016/j.radonc.2008.10.006


  • Presentations referencing similar topics